Class Action Lawsuit Against ADMA Biologics: Investor Harm Allegations
On June 15, 2026, Bronstein, Gewirtz & Grossman LLC, a well-respected law firm focused on investor rights, announced the filing of a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) and several of its executives. This legal action aims to recover damages for alleged violations of federal securities laws on behalf of investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, known as the 'Class Period.' Investors who believe they have been negatively impacted by these actions are encouraged to participate in the class action by visiting the firm's website at bgandg.com/ADMA.
The lawsuit claims that during the Class Period, ADMA Biologics and its officials made misleading statements and failed to disclose critical information. Some of the specific allegations include engaging in undisclosed related party transactions, employing channel stuffing tactics to inflate revenue figures, and lacking sufficient internal controls. Such actions reportedly led to materially false and misleading statements made by the defendants, ultimately affecting the business's prospects and operations.
Investors are particularly concerned about these allegations as they may indicate serious discrepancies in how ADMA Biologics managed its reporting and compliance processes. With the integrity of the company now under scrutiny, the class action lawsuit seeks to hold the defendants accountable and ensure that all investors can seek justice for their financial losses.
Following the filing of the lawsuit, investors who suffered losses related to ADMA are encouraged to act swiftly—specifically, they have until August 10, 2026, to request the court to appoint them as lead plaintiffs. Interested parties should note that participation as a lead plaintiff is not required to share in any recovery that the class may achieve.
One key aspect of the legal representation from Bronstein, Gewirtz & Grossman LLC is that they work on a contingency fee basis. This means that clients do not have to pay attorney fees unless the case is successful, allowing investors to pursue justice without upfront financial concerns.
As stated by Peretz Bronstein, the founding partner of the firm, 'Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.' This commitment to upholding investor rights and demanding corporate accountability is what sets Bronstein, Gewirtz & Grossman, LLC apart in the realm of securities class action lawsuits.
For those who want to stay updated on this ongoing situation or contribute information, they can follow the firm on social media platforms like LinkedIn, X, Facebook, or Instagram.
In today's challenging investment environment, being aware of potential investments' risks and the legal landscape is crucial. The situation with ADMA Biologics underscores the need for proper corporate governance and transparency. Investors should remain vigilant and informed as further developments unfold with this class action and watch for the outcomes that may arise from this legal challenge.
The lawsuit claims that during the Class Period, ADMA Biologics and its officials made misleading statements and failed to disclose critical information. Some of the specific allegations include engaging in undisclosed related party transactions, employing channel stuffing tactics to inflate revenue figures, and lacking sufficient internal controls. Such actions reportedly led to materially false and misleading statements made by the defendants, ultimately affecting the business's prospects and operations.
Investors are particularly concerned about these allegations as they may indicate serious discrepancies in how ADMA Biologics managed its reporting and compliance processes. With the integrity of the company now under scrutiny, the class action lawsuit seeks to hold the defendants accountable and ensure that all investors can seek justice for their financial losses.
Following the filing of the lawsuit, investors who suffered losses related to ADMA are encouraged to act swiftly—specifically, they have until August 10, 2026, to request the court to appoint them as lead plaintiffs. Interested parties should note that participation as a lead plaintiff is not required to share in any recovery that the class may achieve.
One key aspect of the legal representation from Bronstein, Gewirtz & Grossman LLC is that they work on a contingency fee basis. This means that clients do not have to pay attorney fees unless the case is successful, allowing investors to pursue justice without upfront financial concerns.
As stated by Peretz Bronstein, the founding partner of the firm, 'Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.' This commitment to upholding investor rights and demanding corporate accountability is what sets Bronstein, Gewirtz & Grossman, LLC apart in the realm of securities class action lawsuits.
For those who want to stay updated on this ongoing situation or contribute information, they can follow the firm on social media platforms like LinkedIn, X, Facebook, or Instagram.
In today's challenging investment environment, being aware of potential investments' risks and the legal landscape is crucial. The situation with ADMA Biologics underscores the need for proper corporate governance and transparency. Investors should remain vigilant and informed as further developments unfold with this class action and watch for the outcomes that may arise from this legal challenge.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.